We describe variation at the PAH locus in the population of Quebec. We successfully analyzed 135 of 141 chromosomes from phenylketonuria (PKU) probands ( 
Introduction
Range expansion by Europeans has been a major demographic feature of human history in the current millennium. 1 Three separate phases of European settlement occurred to account for the richly diverse history of the region of North America called Quebec, where resides one of the best documented populations in the world. [2] [3] [4] [5] [6] French settlers came before 1759; Loyalists from the United States and emigrants from the United Kingdom came after 1759; non-French, non-British settlers arrived in substantial numbers after 1945. Descendants of these settlers are the majority among the nearly 7 million persons comprising the population of Quebec today, and among them are probands with hyperphenylalaninemia (HPA) due to impaired function of phenylalanine hydroxylase enzyme. The corresponding gene (symbol PAH) has been cloned and characterized; [7] [8] [9] [10] rare mutations in it cause disease, notably phenylketonuria (PKU), 11 and the diseasecausing alleles are widely ascertained by screening newborns for HPA. The probands described in the present report were ascertained in this manner. Accordingly, their allelic variation at the PAH locus could be used as markers for the demographic sources of and genetic variation in the population of Quebec.
The PAH gene harbours over 328 different mutations (see http://www.mcgill.ca/pahdb); it also has a set of polymorphic alleles in apparent linkage disequilibrium from which polymorphic haplotypes can be generated. 10, [12] [13] [14] [15] [16] Mutations and polymorphic haplotypes, along with descriptors of attributes and relationships, are recorded in a relational database (PAHdb) curated and maintained on behalf of the PAH Mutation Analysis Consortium. 17 In the present report, the fourth in a series, [18] [19] [20] we describe 45 different PAH mutations in probands with HPA, some causing PKU, others causing non-PKU HPA, all ascertained by newborn screening in the Quebec population over the past 20 years; they include ten novel mutations first identified in this population. Some mutations, otherwise identical-by-state, provided evidence for recurrent mutation or intragenic recombination to explain their distribution on multiple polymorphic haplotype backgrounds. PAH mutations stratify in Quebec by geographic region and population history. Accordingly, our findings have historical and medical as well as genetic interest.
Materials and Methods

The Sample
From a recent epidemiological analysis 21 of newborn screening in Quebec between 1973 and 1990, we ascertained probands with HPA and subdivided them into PKU (classical and variant forms) or non-PKU HPA. The criteria for classification are described elsewhere. 11 We obtained sufficient DNA from 141 independent chromosomes in probands with PKU and completed analysis on 135 (95.7% of the sample). In a related project, we began the analysis of chromosomes from 13 probands with non-PKU HPA; data on eight chromosomes are included here for comparison with the set of PKU-causing mutations. There are no probands of Aboriginal, Oriental or African ancestry in the sample. The project was reviewed and approved for ethics by the Institutional Review Board (Montreal Children's Hospital).
Geographic Features
We stratified findings by geographic region. 'Eastern Quebec' is the settled region east of the city of Three Rivers; its population is French Canadian, with a well-documented pattern of settlement and expansion. 22, 23 'Western Quebec' is the corresponding region west of the river; it has a largely French Canadian population and a demographic history different from that in Eastern Quebec. 'Montreal' refers to the region of greater Montreal and environs, where the non-French Canadian component of the Quebec population is predominantly located. The DNA samples were obtained from probands attending the regional medical centers at Laval, Montreal and McGill universities respectively.
Mutation Detection
We used 'broad range', denaturing gradient gel electrophoresis (DGGE) to analyze all exons and flanking regions of intron sequences in the PAH gene, after amplification by PCR from designated GC-clamped primers. 24, 25 Mutant exons were amplified with non-clamped primers, and sequenced using the dsDNA cycle sequencing system (Gibco BRL). Novel mutations were confirmed on second PCR sample by sequencing, selective restriction analysis, artificially created restriction sites, or hybridization with allele-specific oligonucleotides.
Mutations are named 26, 27 using the convention of the PAH Mutation Analysis Consortium, i.e. by 'trivial names' which describe the effect of the allele on gene transcription and translation; the corresponding systematic (nucleotide) names are given in the PAH Mutation Database.
Haplotype Analysis
We used seven diallelic (RFLP) and two multiallelic polymorphic sites at the PAH locus 12, 13, 15 to describe the relationships with mutations and haplotype background, as described previously. 20 
Calculation of Homozygosity (j)
Homozygosity (j) at the PAH locus was calculated for the whole population and for each regional population by the formula j = Σx 2 i , where x i is the frequency of each allele; the uncharacterized alleles (chromosomes) were given the frequency 1/N where N is the total number of mutant chromosomes.
The PAH Mutation Database
This curated locus-specific mutation database 17, 28 is relational in design and contains information on over 328 different mutations (entities), with attributes, relationships (eg to haplotypes and populations), and other details. Data are copied from PAHdb (Logical Views) and periodically posted on the Internet (http://www.mcgill.ca/pahdb). A search engine is now available (Nowacki P, K Hechtman, CR Scriverunpublished data). We used the database to compare findings in Quebec and elsewhere.
Terminology
The term 'disease-causing' implies mutations causing hyperphenylalaninemia (HPA). The terms 'chromosome', 'allele' and 'mutation' are used both according to their conventional definitions 29 and in particular contexts here. Chromosome is the operative word describing the physical source in the blood sample of the DNA analyzed at the PAH locus (chromosome 12q24.1). Mutation is the equivalent of muton 29 and refers to the smallest unit of DNA changed in the PAH nucleotide sequence; each mutation is named according to convention 26, 27 (see also http://www.mcgill.ca/pahdb). Allele, as in 'heteroallelic genotype', means the proband inherited two different mutons in trans at the PAH locus; homoallelic implies identical mutons. A mutation may be identicalby-state on different chromosomes (alleles) but not identicalby-descent; we used mutation-haplotype associations (alleles) to distinguish mutations identical-by-state from those identical-by-descent.
Results
The PAH Mutations in Quebec
We identified 45 different PAH mutations on 135 PKU chromosomes and on eight additional non-PKU HPA chromosomes in the Quebec probands ( Figure 1 ). Seven mutations, each unlikely to be disease-causing, were found in cis with a disease-causing mutation; they are: i) three apparent polymorphisms in introns of which two were previously known (IVS2nt19t→c and IVS3nt-22c→t) and the third, heretofore unknown (IVS6nt-55t→c); ii) four silent polymorphisms in codons (Q232Q, V245V, L385L, Y414Y), all previously known and each useful as an intragenic marker.
The other 38 mutations are apparently diseasecausing, many having been analyzed by in vitro expression analysis 30 as indicated in Table 1 ; i) four are 
Figure 1 The human PAH gene (~100 kb on chromosome 12q24.1) showing distribution of exons (bars) and introns (white boxes
Novel Mutations Three mutations are reported
here for the first time (data seen by reviewers and documented formally elsewhere). 31 Two are diseasecausing: c.125A→T (K42I) on haplotype 21; and [c.470G→A; c.471A→C] (R157N) on an undetermined haplotype. Each occurred on a single chromosome. K42I occurred in a proband with classical PKU in a 'functionally hemizygous' PAH genotype (K42I/E280K). The R157N mutation, found in a patient with PKU, involves a dinucleotide substitution and it curtails the measured activities of PAH enzyme both in vitro and in vivo. 32 The third allele is a polymorphism (IVS6nt-55a/c); it was found on three different PKU and control chromosomes (relative frequency 1.4%).
Whether it has any effect on phenotype is not known.
Unusual Identical-by-State Mutations Four
PKU-causing mutations were found, in this phase of the project, to be identical-by-state on two different polymorphic haplotype backgrounds ( Figure 1 , Table 1 ) can each be explained by a single intragenic recombination (data shown elsewhere). 31 The fourth mutation (IVS12nt1) was found on either haplotype 44 or 45; this unique association (IVS12nt1 is otherwise almost exclusively on haplotype 3) is unresolved because of technical difficulties with the EcoRV site; nonetheless, a double intragenic recombination would be necessary to explain it.
Two other identical-by-state mutations with unusual haplotype relationships, each first reported in Quebec, were found again in this phase of the project (Table 1) . They are R408W on haplotype 1 18, 19 and E280K on haplotype 2. 20 In both cases, the finding is compatible with recurrent mutation involving a CpG site. 36, 37 Mutational Heterogeneity in Quebec The observed frequency of homoallelic PKU genotypes was 24%. We used the sets of PKU-causing mutations (Table 1) to calculate homozygosity (j) at the PAH locus for the Quebec population as a whole and by region. The value for Quebec is 0.06; values are slightly higher in the Montreal and eastern regions and lower in Western Quebec.
Mutation Types in Quebec and the World
The relative frequency distributions of mutation types are similar in Quebec and the world (Figure 2) . The great majority of mutations are missense. PAH deletions rarely involve more than one or a few nucleotides (http://www.mcgill.ca/pahdb). Insertions are also small and there are none in the Quebec sample. Polymorphisms are not included in Figure 2 because they are underestimated in the world sample whereas their detection has been efficient using DGGE in the Quebec sample.
Effect of Mutations on Phenotype
Whether all 34 mutations associated with PKU (Table  1) , or the four mutations associated with non-PKU HPA inherited in functionally hemizygous or homoallelic genotypes (T92I, E390G, R408Q, and D415N, Figure) , impair PAH enzyme function in vivo is unknown. However, 16 of the PKU mutations and one non-PKU HPA mutation (R408Q) have been studied in vitro by expression analysis 30, 32 and Table 1 ; they all impair catalytic activity. By their nature, the other 20 mutations are also likely to alter PAH enzyme activity. The corresponding in vivo genotype-phenotype relationships have been documented in detail elsewhere 38 (see also PAH database). Whether all of those designated as neutral polymorphisms are without any phenotypic effect is unknown.
Geographic Stratification of Alleles
There is non-random distribution of PAH alleles by geographic region in Quebec (Table 1 ) and the 12 most prevalent mutations (PKU and non-PKU HPA causing) stratify by geographic region (Figure 3) . The distributions are compatible with different demographic histories for the three regions.
Discussion
Hereditary metabolic diseases, albeit individually rare in prevalence, are important sources of knowledge about human genetic disease in general. From mutation detection by current methods, 39, 40 each of the corresponding loci has revealed extensive locus-specific allelic variation. Whereas a few mutations at each locus may be prevalent and shared widely among probands, most disease-causing mutations are rare, their histories coinciding with those of families and defined populations and probably identical by descent. 41 The record of mutations in the PAH gene is no exception to this emerging view.
Probands with hyperphenylalaninemia, notably PKU, are being ascertained with high efficiency wherever newborn screening takes place. Accordingly, the sample of mutant chromosomes available for analysis of the PAH gene is large, worldwide, originates in the populations of at least 28 countries, and harbours more than 328 different mutations. 17 When these PAH mutations are analyzed for their relationships with polymorphic haplotypes, populations of origin, and geographic distributions, 42 the majority that are disease-causing are indeed rare; no more than five being prevalent among Europeans: they are I65T, IVS10nt-11, IVS12nt1, R408W on haplotype 1 and R408W on haplotype 2 (the latter a recurrent mutation) 36 and they account for about two-thirds of the known European PAH mutations. Whereas the aggregate frequency of PKU mutations is only about 1% in European genomes, 11, 43 individually they are useful markers of human history, 42 notably of European range expansion to Australia, 44 South America 45 and North America. 46 We can now see how their presence in Quebec populations reflects a well-documented range expansion in three different phases after 1600 AD, first from France, then from Great Britain, and lately from other regions of Europe and the world. The Quebec PAH mutations (Figure 1 ) validate demographic and historical hypotheses and interrogate mutation mechanisms. The rare (disease-causing) and polymorphic (neutral) alleles on PKU chromosomes in the Quebec population (Table 1) , tell us the following:
i) The majority ( > 80%) of the phenotype-modifying (disease-causing) mutations occur at low iii) The distribution of various PAH alleles in French Canadians is compatible with founder effect and genetic drift, for example: a) M1V, a rare allele in v) The Quebec project has generated useful hypotheses about the molecular mechanisms underlying mutations at the PAH locus, for example: a) from the discovery of European mutations identicalby-state but on multiple haplotypes in the Quebec population (eg R408W on H1, 18 and E280K on H2) 19 came evidence for recurrent mutations at CpG dinucleotides in the gene. 36, 37 These findings encouraged an analysis of predicted mutability in the coding sequence of the PAH gene. 37 b) From the analysis of other mutations again identicalby-state yet on multiple haplotypes has come evidence for intragenic recombination in the 100 kb PAH gene; accordingly, these mutations (S67P, G218V, V245A and IVS12nt1) are identical by descent. vi) Discovery of the recurrent R408W and the I65T mutation in Quebec, along with revealing geneaological reconstructions, 19 led to enquiries about their European origins and how they came to be markers of range expansion. The R408W mutation on haplotype 1, and I65T on haplotype 9, are now seen to cluster in North Western Europe along its Atlantic borders, 50,51 the regions from which settlers of New France/Lower Canada largely came prior to 1945.
vii) The profile of mutation types (Figure 2 ) at the PAH locus in the Quebec poopulation is similar to that found world-wide and in particular to that reported for the United States; 46 family studies have so far ruled out any de novo PAH mutation in Quebec. The findings imply that demography and human history, rather than environmental mutagenesis for example, explain the PAH mutation profile in these New World populations. Nor is the frequency of unidentified PKU-causing mutations in the Quebec sample exceptional; it may reflect a limitation of the DGGE method, but it is equally likely that these reclusive mutations could occur in the non-coding regions of the gene (although prior searches in the 5' region of the PAH gene have been unfruitful on otherwise uninformative 'PKU' chromosomes. 52 In summary, from a careful study of PAH mutations in a well-defined New World population (Quebec), it has been possible to document molecular mechanisms generating genomic diversity (eg recurrent mutation and intragenic recombination) and to trace historical events underlying the genetic variation observed in the population (such as range expansion and genetic drift, during the past 400 years). Furthermore, our model shows how it might be possible, despite the difficulties inherent in extensive allelic heterogeneity for mutation diagnosis, 39, 40 to apply knowledge about population genetic variation to efficient prediction, treatment and prevention of a genetic disease. database but also controlled the electrons producing this 'manuscript'.
